Rafael (NYSE:RFL) Lowered to “Sell” Rating by Wall Street Zen

Rafael (NYSE:RFL) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Friday.

Rafael Stock Performance

NYSE:RFL opened at $1.45 on Friday. Rafael has a 52-week low of $1.28 and a 52-week high of $3.19. The stock has a fifty day moving average of $1.78 and a 200 day moving average of $1.74. The firm has a market capitalization of $50.88 million, a price-to-earnings ratio of -1.54 and a beta of 0.89.

Rafael (NYSE:RFL) last announced its earnings results on Wednesday, June 11th. The company reported ($0.19) earnings per share for the quarter. Rafael had a negative return on equity of 24.75% and a negative net margin of 3,127.60%.The business had revenue of $0.36 million during the quarter.

Institutional Investors Weigh In On Rafael

Several hedge funds have recently bought and sold shares of the stock. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Rafael during the 1st quarter valued at $26,000. Simplex Trading LLC purchased a new stake in Rafael during the second quarter valued at about $32,000. Marshall Wace LLP purchased a new stake in Rafael during the second quarter valued at about $50,000. Americana Partners LLC bought a new stake in Rafael during the second quarter worth about $76,000. Finally, Cable Car Capital LP purchased a new position in shares of Rafael in the 2nd quarter worth about $173,000. 11.30% of the stock is currently owned by institutional investors.

About Rafael

Rafael Holdings, Inc primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells.